SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Susan B. Anthony

PatientSusan B. Anthony
Date of birth1941-02-15
IdentifiersMRN HR-NI014-SYN; SSN (made up) 000-14-7302
Document date2026-03-30
AuthorHarold Pemberton, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Two-week heart failure medication safety check. [S]

History of Present Illness

Miss Anthony returns two weeks after starting furosemide and empagliflozin for newly diagnosed heart failure. She is less breathless and now climbs a flight of stairs with one pause instead of two. Her ankle swelling is gone by morning and returns only slightly in the evening. Her home weights have fallen steadily by about 1.7 kg. She has had no dizziness on standing, no excess thirst, and no genital itching or urinary symptoms since starting empagliflozin. She takes every dose and keeps a weight diary. Her echocardiogram and cardiology consultation were done this morning. [S]

ElementDetail
Interval changeLess breathless on stairs; evening ankle swelling only
Weight diaryDown about 1.7 kg over two weeks
Medication toleranceNo dizziness, thirst, or genital or urinary symptoms
AdherenceEvery dose taken
NYHA classII, improved from II to III

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever or fatigue beyond her usual after travel
CardiovascularPositiveMild evening ankle swelling; no chest pain, palpitations, or orthopnea
RespiratoryPositiveBreathless after a flight of stairs; no cough or wheeze
GenitourinaryNegativeNo dysuria, genital itching, or urgency
NeurologicalNegativeNo dizziness or lightheadedness on standing

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Furosemide 20 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-03-16 to 2026-06-29completedS
Empagliflozin 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-03-16activeS
Spironolactone 25 mg oral tablet, one-half tablet (12.5 mg) by mouth dailyOne-half tablet by mouth dailyOral route2026-03-30activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-03-30Body height165cmS
2026-03-30Body weight56.8kgS
2026-03-30Body mass index (BMI) [Ratio]20.9kg/m2S
2026-03-30Systolic blood pressure146mm[Hg]S
2026-03-30Diastolic blood pressure80mm[Hg]S
2026-03-30Heart rate78/minS
2026-03-30Respiratory rate18/minS
2026-03-30Body temperature36.6CelS
2026-03-30Oxygen saturation in Arterial blood by Pulse oximetry96%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-03-30Sodium [Moles/volume] in Serum or Plasma137mmol/L135-145 mmol/LNormalS
2026-03-30Potassium [Moles/volume] in Serum or Plasma3.9mmol/L3.5-5.1 mmol/LNormalS
2026-03-30Creatinine [Mass/volume] in Serum or Plasma0.96mg/dL0.59-1.04 mg/dLNormalS
2026-03-30Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M58mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
2026-03-30Glucose [Mass/volume] in Serum or Plasma94mg/dL70-99 mg/dLNormalS
2026-03-30Magnesium [Mass/volume] in Serum or Plasma1.9mg/dL1.6-2.6 mg/dLNormalS
2026-03-30Left ventricular Ejection fraction62%50-70%NormalS
2026-03-30Left atrial End-systolic volume (by US.2D+Calculated by biplane method of disks)/Body surface area42mL/m2<=34 mL/m²HighS
2026-03-30Heart valve E velocity/Annulus E wave by US16{ratio}<=14HighS

Physical Exam

Vital signs recorded on 2026-03-30; see the Vital Signs section. [S]

SystemFinding
GeneralAlert, comfortable, speaking easily
NeckJugular venous pressure 7 cm, down from 10 cm at intake
LungsClear; the basal crackles heard at intake are gone
HeartRegular rhythm; S4; no murmur
ExtremitiesTrace ankle edema, down from 2+ at intake

Problems

ProblemClinical statusVerificationCodeProvenance
Heart failure with preserved ejection fraction, NYHA class II to III at diagnosis; synthetic modern diagnosis linked to the documented 1906 heart failureactiveconfirmed I50.32S — Synthetic diagnosis confirmed by echocardiogram in the modern episode; the 1906 cause of death remains D.
Hypertensive heart disease with heart failureactiveconfirmed I11.0S — Synthetic diagnosis; no blood pressure from her lifetime is recorded in the cited sources.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryBasic metabolic panel with magnesium1 to 2 weeks after starting or changing therapy; every 3 to 6 months when stableCompleted todayTwo weeks after starting furosemide and empagliflozin. Sodium, potassium, creatinine, and magnesium normal; eGFR 58, a small expected fall
ImagingTransthoracic echocardiogramAt diagnosis; repeat only with unexplained changeCompleted todayEjection fraction 62 percent, left atrial volume index 42 mL/m², E/e' 16: heart failure with preserved ejection fraction
ExaminationBlood pressure, heart rate, weight, jugular venous pressure, edema, lungsEvery visitCompleted todayWeight down 1.7 kg; jugular venous pressure and edema improved
SurveyNYHA functional classEvery visitCompleted todayClass II
SurveyKCCQ-12Baseline, then every 3 to 6 monthsUp to dateBaseline 52 at intake; next at the three-month review
ReferralCardiology evaluation for specific causesAt diagnosisCompleted todaySeen today. Cardiac amyloidosis is not suspected: septal thickness 11 mm, voltage criteria for left ventricular hypertrophy on the ECG, and no carpal tunnel or neuropathy
Medication safetySGLT2 inhibitor toleranceEach visit while startingCompleted todayNo volume depletion, genital infection, or urinary infection
Self-managementDaily weight diaryEvery visitCompleted todayReviewed; she records every morning

Goal progress:

Immunizations given today: Pneumococcal conjugate vaccine PCV20; Respiratory syncytial virus vaccine, single dose [S]

Guideline basis: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction (2023); CMID: Clinical Monitoring Intelligence Database, heart failure monograph (2026)

Follow-up: Basic metabolic panel in one to two weeks after starting spironolactone. Heart failure review in three months. Next scheduled visit 2026-06-29: three-month heart failure and blood pressure review. [S]